Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer. Founded by Erik Berg and Hans van der Vliet in 2016, Lava Therapeutics is backed by investors that include Redmile Group, MRL Ventures Fund, Sanofi Ventures, Ysios Capital, and Gilde Healthcare and is headquartered in Utrecht.